13F filing recap · Q2 2023
What did ArrowMark Partners buy in Q2 2023?
Reported stock-position changes between this filing and the previous one. US-listed stocks across every ArrowMark account, including accounts that belong to no fund below.
Stock value
$9.11B
Positions
302
Estimated turnover
27.0%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
New positions
RBARb Global, Inc$269.90Mreported value+4.50M sharesEYENational Vision Holdings, Inc.$53.98Mreported value+2.22M sharesBJBj’s Wholesale Club Holdings, Inc.$34.06Mreported value+540.5K sharesABCLAbcellera Biologics Inc.$26.52Mreported value+4.11M sharesATMUAtmus Filtration Technologies Inc.$12.23Mreported value+557.1K sharesSVVSavers Value Village, Inc.$7.70Mreported value+325.0K sharesCWANClearwater Analytics Holdings, Inc.$6.71Mreported value+422.8K sharesDHDefinitive Healthcare Corp.$5.23Mreported value+475.3K sharesPLRXPliant Therapeutics, Inc.$5.10Mreported value+281.2K sharesANGIAngi Inc.$4.23Mreported value+1.28M sharesCLVTClarivate Plc$4.20Mreported value+441.0K sharesIMGNImmunogen Inc$3.10Mreported value+164.5K sharesSAMThe Boston Beer Company, Inc.$3.08Mreported value+10.0K sharesZNTLZentalis Pharmaceuticals, Inc.$2.47Mreported value+87.6K sharesROIVRoivant Sciences Ltd.$927.4Kreported value+92.0K sharesCPCanadian Pacific Kansas City Ltd/cn$869.3Kreported value+10.8K sharesWSCWillscot Holdings Corporation$530.5Kreported value+11.1K sharesMLTXMoonlake Immunotherapeutics$510.0Kreported value+10.0K shares